REMLIFE
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
-
Share Price
-
Financials
-
Revenue mix
-
Shareholdings
-
Peers
-
Forensics
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
This data is currently unavailable for this company.
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
| (In Cr.) |
|---|
| (In Cr.) | ||||
|---|---|---|---|---|
|
This data is currently unavailable for this company. |
| (In %) |
|---|
| (In Cr.) |
|---|
| Financial Year (In Cr.) |
|---|
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Recent events
-
News
-
Corporate Actions
Remedium Lifecare Global Export Expansion
Aug 25 (Reuters) - Remedium Lifecare Ltd REMU.BO:
REMEDIUM LIFECARE LTD - PLANS GLOBAL EXPORT EXPANSION
Source text: ID:nBSE5vSRyV
Further company coverage: REMU.BO
(([email protected];))
Aug 25 (Reuters) - Remedium Lifecare Ltd REMU.BO:
REMEDIUM LIFECARE LTD - PLANS GLOBAL EXPORT EXPANSION
Source text: ID:nBSE5vSRyV
Further company coverage: REMU.BO
(([email protected];))
Remedium Lifecare To Raise Up To 500 Mln Rupees Via Rights Issue
Jan 22 (Reuters) - Remedium Lifecare Ltd REMU.BO:
TO RAISE UP TO 500 MILLION RUPEES VIA RIGHTS ISSUE
Source text: ID:nBSEXmjnS
Further company coverage: REMU.BO
(([email protected];;))
Jan 22 (Reuters) - Remedium Lifecare Ltd REMU.BO:
TO RAISE UP TO 500 MILLION RUPEES VIA RIGHTS ISSUE
Source text: ID:nBSEXmjnS
Further company coverage: REMU.BO
(([email protected];;))
Remedium Lifecare Denies Receiving Order From Eli Lilly
Jan 7 (Reuters) - Remedium Lifecare Ltd REMU.BO:
REMEDIUM LIFECARE LTD - DENIES RECEIVING ORDER FROM ELI LILLY
REMEDIUM LIFECARE - CALLS MEDIA REPORTS CLAIMING CO GOT ORDER FROM ELI LILLY SPECULATIVE, UNFOUNDED
Source text: ID:nBSE4r2PMk
Further company coverage: REMU.BO
(([email protected];))
Jan 7 (Reuters) - Remedium Lifecare Ltd REMU.BO:
REMEDIUM LIFECARE LTD - DENIES RECEIVING ORDER FROM ELI LILLY
REMEDIUM LIFECARE - CALLS MEDIA REPORTS CLAIMING CO GOT ORDER FROM ELI LILLY SPECULATIVE, UNFOUNDED
Source text: ID:nBSE4r2PMk
Further company coverage: REMU.BO
(([email protected];))
Remedium Lifecare To Raise Funds Up To $25 Mln
Sept 4 (Reuters) - Remedium Lifecare Ltd REMU.BO:
TO RAISE FUNDS UP TO $25 MILLION
Source text for Eikon: ID:nBSE2lHP2l
Further company coverage: REMU.BO
(([email protected];;))
Sept 4 (Reuters) - Remedium Lifecare Ltd REMU.BO:
TO RAISE FUNDS UP TO $25 MILLION
Source text for Eikon: ID:nBSE2lHP2l
Further company coverage: REMU.BO
(([email protected];;))
Remedium Lifecare To Consider Acquisition Of Co In Specialty Chemicals Sector
July 15 (Reuters) - Remedium Lifecare Ltd REMU.BO:
REMEDIUM LIFECARE - TO CONSIDER ACQUISITION OF CO IN SPECIALTY CHEMICALS SECTOR
REMEDIUM LIFECARE LTD - ACQUISITION VALUE EXPECTED TO BE AROUND 10 BILLION RUPEES
Source text for Eikon: ID:nBSE1RqyGK
Further company coverage: REMU.BO
(([email protected];))
July 15 (Reuters) - Remedium Lifecare Ltd REMU.BO:
REMEDIUM LIFECARE - TO CONSIDER ACQUISITION OF CO IN SPECIALTY CHEMICALS SECTOR
REMEDIUM LIFECARE LTD - ACQUISITION VALUE EXPECTED TO BE AROUND 10 BILLION RUPEES
Source text for Eikon: ID:nBSE1RqyGK
Further company coverage: REMU.BO
(([email protected];))
Remedium Lifecare Gets Supply Contract From Pharmac Distribution Co In United Kingdom
June 25 (Reuters) - Remedium Lifecare Ltd REMU.BO:
RECEIVED MULTI-YEAR SUPPLY CONTRACT FROM PHARMACEUTICAL DISTRIBUTION CO IN UNITED KINGDOM
CONTRACT INVOLVES SUPPLY OF ACTIVE PHARMACEUTICAL INGREDIENTS, INTERMEDIATES, AND SPECIALTY CHEMICALS
SUPPLIES SCHEDULED BETWEEN JULY 2024 AND JUNE 2025 VALUED AT 1.75 BILLION RUPEES
Source text for Eikon: ID:nBSE7M9jBH
Further company coverage: REMU.BO
(([email protected];))
June 25 (Reuters) - Remedium Lifecare Ltd REMU.BO:
RECEIVED MULTI-YEAR SUPPLY CONTRACT FROM PHARMACEUTICAL DISTRIBUTION CO IN UNITED KINGDOM
CONTRACT INVOLVES SUPPLY OF ACTIVE PHARMACEUTICAL INGREDIENTS, INTERMEDIATES, AND SPECIALTY CHEMICALS
SUPPLIES SCHEDULED BETWEEN JULY 2024 AND JUNE 2025 VALUED AT 1.75 BILLION RUPEES
Source text for Eikon: ID:nBSE7M9jBH
Further company coverage: REMU.BO
(([email protected];))
Remedium Lifecare To Acquire Manufacturing Facility In Hyderabad For 380 Mln Rupees
March 7 (Reuters) - Remedium Lifecare Ltd REMU.BO:
PROPOSED TO ACQUIRE A MANUFACTURING FACILITY IN HYDERABAD
MANUFACTURING UNIT DEAL FOR 380 MILLION RUPEES
WITH THIS ACQUISITION, CO WILL BRANCH INTO MANUFACTURING OF PHARMACEUTICAL INTERMEDIATES
EXPECT TO CLOSE TRANSACTION WITHIN 30TH JUNE 2024
Source text for Eikon: ID:nBSE6nC1J6
Further company coverage: REMU.BO
(([email protected];))
March 7 (Reuters) - Remedium Lifecare Ltd REMU.BO:
PROPOSED TO ACQUIRE A MANUFACTURING FACILITY IN HYDERABAD
MANUFACTURING UNIT DEAL FOR 380 MILLION RUPEES
WITH THIS ACQUISITION, CO WILL BRANCH INTO MANUFACTURING OF PHARMACEUTICAL INTERMEDIATES
EXPECT TO CLOSE TRANSACTION WITHIN 30TH JUNE 2024
Source text for Eikon: ID:nBSE6nC1J6
Further company coverage: REMU.BO
(([email protected];))
Remedium Lifecare Got Export Order Of 1.69 Billion Rupees
Feb 28 (Reuters) - Remedium Lifecare Ltd REMU.BO:
GOT EXPORT ORDER OF 1.69 BILLION RUPEES FROM PHARMYKA GENERAL TRADING LLC
Further company coverage: REMU.BO
(([email protected];))
Feb 28 (Reuters) - Remedium Lifecare Ltd REMU.BO:
GOT EXPORT ORDER OF 1.69 BILLION RUPEES FROM PHARMYKA GENERAL TRADING LLC
Further company coverage: REMU.BO
(([email protected];))
Remedium Lifecare To Consider Acquisition Of Manufacturing Facility
Feb 23 (Reuters) - Remedium Lifecare Ltd REMU.BO:
TO CONSIDER ACQUISITION OF MANUFACTURING FACILITY NEAR HYDERABAD
Source text for Eikon: ID:nBSE3rk5p6
Further company coverage: REMU.BO
(([email protected];;))
Feb 23 (Reuters) - Remedium Lifecare Ltd REMU.BO:
TO CONSIDER ACQUISITION OF MANUFACTURING FACILITY NEAR HYDERABAD
Source text for Eikon: ID:nBSE3rk5p6
Further company coverage: REMU.BO
(([email protected];;))
Remedium Lifecare Dec-Qtr Profit Rises
Feb 14 (Reuters) - Remedium Lifecare Ltd REMU.BO:
REMEDIUM LIFECARE DEC-QUARTER PROFIT 687.8 MILLION RUPEES VERSUS PROFIT 15.2 MILLION RUPEES
REMEDIUM LIFECARE DEC-QUARTER REVENUE FROM OPERATIONS 18.34 BILLION RUPEES VERSUS 1.76 BILLION RUPEES
Source text for Eikon: ID:nBSE2DDtCQ
Further company coverage: REMU.BO
(([email protected];;))
Feb 14 (Reuters) - Remedium Lifecare Ltd REMU.BO:
REMEDIUM LIFECARE DEC-QUARTER PROFIT 687.8 MILLION RUPEES VERSUS PROFIT 15.2 MILLION RUPEES
REMEDIUM LIFECARE DEC-QUARTER REVENUE FROM OPERATIONS 18.34 BILLION RUPEES VERSUS 1.76 BILLION RUPEES
Source text for Eikon: ID:nBSE2DDtCQ
Further company coverage: REMU.BO
(([email protected];;))
Remedium Lifecare Ltd- To Consider And Approve Sub-Division Of Shares
Remedium Lifecare Ltd REMU.BO:
REMEDIUM LIFECARE LTD- TO CONSIDER AND APPROVE SUB-DIVISION OF SHARES
Source text for Eikon: ID:nBSE34VZ2s
Further company coverage: REMU.BO
Remedium Lifecare Ltd REMU.BO:
REMEDIUM LIFECARE LTD- TO CONSIDER AND APPROVE SUB-DIVISION OF SHARES
Source text for Eikon: ID:nBSE34VZ2s
Further company coverage: REMU.BO
Remedium Lifecare To Consider Issue Of Bonus Shares
June 14 (Reuters) - Remedium Lifecare Ltd REMU.BO:
TO CONSIDER ISSUE OF BONUS SHARES
TO CONSIDER INCREASING BORROWING LIMIT FROM 500 MILLION RUPEES TO 10 BILLION RUPREES BY ISSUANCE OF DEBT SECURITIES
TO CONSIDER LIMIT FOR INVESTMENT VIA ACQUISITION OF ASSET UPTO 10 BLN RUPEES
TO CONSIDER SUB-DIVISION OF SHARES
Source text for Eikon: ID:nBSE4TDrQf
Further company coverage: REMU.BO
(([email protected];))
June 14 (Reuters) - Remedium Lifecare Ltd REMU.BO:
TO CONSIDER ISSUE OF BONUS SHARES
TO CONSIDER INCREASING BORROWING LIMIT FROM 500 MILLION RUPEES TO 10 BILLION RUPREES BY ISSUANCE OF DEBT SECURITIES
TO CONSIDER LIMIT FOR INVESTMENT VIA ACQUISITION OF ASSET UPTO 10 BLN RUPEES
TO CONSIDER SUB-DIVISION OF SHARES
Source text for Eikon: ID:nBSE4TDrQf
Further company coverage: REMU.BO
(([email protected];))
Events:
Rights
Bonus
Split
Split
Bonus
More Nano Cap Ideas
See similar 'Nano' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
-
Business
-
Financials
-
Share Price
-
Shareholdings
What does Supha Pharmachem do?
Remedium Lifecare Ltd. is a pharmaceutical company specializing in the manufacture and sale of APIs and Intermediates for innovator and generic pharmaceutical players in domestic and international markets.
Who are the competitors of Supha Pharmachem?
Supha Pharmachem major competitors are Yuvraaj Hygiene Prod, Anmol India, Future Consumer, Filtra Consultants, Amrapali Industries, Binny Mills, Rubra Medicaments. Market Cap of Supha Pharmachem is ₹75 Crs. While the median market cap of its peers are ₹74 Crs.
Is Supha Pharmachem financially stable compared to its competitors?
Supha Pharmachem seems to be less financially stable compared to its competitors. Altman Z score of Supha Pharmachem is 0.28 and is ranked 6 out of its 8 competitors.
Does Supha Pharmachem pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Supha Pharmachem latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%
How has Supha Pharmachem allocated its funds?
Companies resources are majorly tied in miscellaneous assets
How strong is Supha Pharmachem balance sheet?
Supha Pharmachem balance sheet is weak and might have solvency issues
Is the profitablity of Supha Pharmachem improving?
The profit is oscillating. The profit of Supha Pharmachem is ₹11.22 Crs for TTM, ₹2.13 Crs for Mar 2025 and ₹32.73 Crs for Mar 2024.
Is the debt of Supha Pharmachem increasing or decreasing?
The net debt of Supha Pharmachem is decreasing. Latest net debt of Supha Pharmachem is ₹1,086 Crs as of Sep-25. This is less than Mar-25 when it was ₹1,139 Crs.
Is Supha Pharmachem stock expensive?
Supha Pharmachem is expensive when considering the EV/EBIDTA, however latest PE is < 3 yr avg PE. Latest PE of Supha Pharmachem is 35.21, while 3 year average PE is 57.12. Also latest EV/EBITDA of Supha Pharmachem is 351 while 3yr average is 235.
Has the share price of Supha Pharmachem grown faster than its competition?
Supha Pharmachem has given lower returns compared to its competitors. Supha Pharmachem has grown at ~36.38% over the last 6yrs while peers have grown at a median rate of 40.02%
Is the promoter bullish about Supha Pharmachem?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Supha Pharmachem is 1.13% and last quarter promoter holding is 1.13%.
Are mutual funds buying/selling Supha Pharmachem?
There is Insufficient data to gauge this.
